can i take semaglutide if i have covid Wegovy reduced deaths from Covid-19? Obesity Drug Wegovy Prevents Covid

Are you tired of trying to shed those stubborn pounds with little to no success

As the use of GLP-1 therapies increase, it will be important to recognize and manage unique adverse events that may arise.

Scientific research shows Mat to be a powerful antioxidant and that it can protect DNA from double-strand breaks

The patient must: Be age 18 or older Have eligible Medicare Part D coverage Be prescribed treatment specifically for weight reduction and maintenance Participate in ongoing nutrition and physical activity intervention Not have already received a GLP-1 through their Part D plan Not be seeking coverage for another Part D-coverable indication, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, MASH, or cardiovascular risk reduction The patient must also have met one of these criteria when GLP-1 therapy was originally started: BMI 35 BMI 30 plus HFpEF, uncontrolled hypertension despite 2 medications, or CKD stage 3a+ BMI 27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease Important: Eligibility is based on BMI at treatment initiation, not necessarily the patients current BMI

Our Scientific Affairs team made the trip to New Orleans for the #ADASciSessions, where we presented new real-world GLP-1 research, including: Better Sleep, More Energy, and Less Daytime Sleepiness on Ro: evaluating sleep apnea outcomes among patients treated with tirzepatide on Ro